Switch theme
Sign up to access all valuation multiples
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
2008
516
LTM Revenue $182M
LTM EBITDA -$1.0M
$673M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SI-BONE has a last 12-month revenue (LTM) of $182M and a last 12-month EBITDA of -$1.0M.
In the most recent fiscal year, SI-BONE achieved revenue of $167M and an EBITDA of -$23.1M.
SI-BONE expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SI-BONE valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $182M | XXX | $167M | XXX | XXX | XXX |
| Gross Profit | $143M | XXX | $132M | XXX | XXX | XXX |
| Gross Margin | 79% | XXX | 79% | XXX | XXX | XXX |
| EBITDA | -$1.0M | XXX | -$23.1M | XXX | XXX | XXX |
| EBITDA Margin | -1% | XXX | -14% | XXX | XXX | XXX |
| EBIT | -$32.7M | XXX | -$35.2M | XXX | XXX | XXX |
| EBIT Margin | -18% | XXX | -21% | XXX | XXX | XXX |
| Net Profit | -$29.0M | XXX | -$30.9M | XXX | XXX | XXX |
| Net Margin | -16% | XXX | -18% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $0.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, SI-BONE's stock price is $18.
SI-BONE has current market cap of $780M, and EV of $673M.
See SI-BONE trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $673M | $780M | XXX | XXX | XXX | XXX | $-0.69 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, SI-BONE has market cap of $780M and EV of $673M.
SI-BONE's trades at 4.0x EV/Revenue multiple, and -29.1x EV/EBITDA.
Equity research analysts estimate SI-BONE's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SI-BONE has a P/E ratio of -26.9x.
See valuation multiples for SI-BONE and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $780M | XXX | $780M | XXX | XXX | XXX |
| EV (current) | $673M | XXX | $673M | XXX | XXX | XXX |
| EV/Revenue | 3.7x | XXX | 4.0x | XXX | XXX | XXX |
| EV/EBITDA | -641.9x | XXX | -29.1x | XXX | XXX | XXX |
| EV/EBIT | -20.6x | XXX | -19.1x | XXX | XXX | XXX |
| EV/Gross Profit | 4.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -26.9x | XXX | -25.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -29.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSI-BONE's last 12 month revenue growth is 17%
SI-BONE's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.
SI-BONE's rule of 40 is -8% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
SI-BONE's rule of X is 42% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for SI-BONE and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | -1% | XXX | -14% | XXX | XXX | XXX |
| EBITDA Growth | -830% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -8% | XXX | 3% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 42% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 70% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 100% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SI-BONE acquired XXX companies to date.
Last acquisition by SI-BONE was XXXXXXXX, XXXXX XXXXX XXXXXX . SI-BONE acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was SI-BONE founded? | SI-BONE was founded in 2008. |
| Where is SI-BONE headquartered? | SI-BONE is headquartered in United States of America. |
| How many employees does SI-BONE have? | As of today, SI-BONE has 516 employees. |
| Who is the CEO of SI-BONE? | SI-BONE's CEO is Ms. Laura A. Francis. |
| Is SI-BONE publicy listed? | Yes, SI-BONE is a public company listed on NAS. |
| What is the stock symbol of SI-BONE? | SI-BONE trades under SIBN ticker. |
| When did SI-BONE go public? | SI-BONE went public in 2018. |
| Who are competitors of SI-BONE? | Similar companies to SI-BONE include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of SI-BONE? | SI-BONE's current market cap is $780M |
| What is the current revenue of SI-BONE? | SI-BONE's last 12 months revenue is $182M. |
| What is the current revenue growth of SI-BONE? | SI-BONE revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of SI-BONE? | Current revenue multiple of SI-BONE is 3.7x. |
| Is SI-BONE profitable? | Yes, SI-BONE is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of SI-BONE? | SI-BONE's last 12 months EBITDA is -$1.0M. |
| What is SI-BONE's EBITDA margin? | SI-BONE's last 12 months EBITDA margin is -1%. |
| What is the current EV/EBITDA multiple of SI-BONE? | Current EBITDA multiple of SI-BONE is -641.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
